Mortality Reducing Therapies in Chronic HFrEF

Mortality Reducing Therapies in Chronic HFrEF: Evidence, Trials & Clinical Impact

Heart failure with reduced ejection fraction (HFrEF) remains a major global cause of morbidity and mortality. Over the past three decades, rigorous randomized controlled trials (RCTs) have transformed management and proven that specific drugs and devices significantly reduce all-cause and cardiovascular mortality.

Below is a comprehensive overview of each mortality-reducing therapy, its approximate relative mortality reduction, and the key landmark trials that shaped current guideline recommendations (AHA/ACC/HFSA & ESC).

---

1. Angiotensin Receptor Blockers (ARBs) — ~12% Mortality Reduction

ARBs emerged as alternatives for patients intolerant to ACE inhibitors.

They reduce afterload, neurohormonal activation, and remodeling.

Landmark Trials

• CHARM-Alternative (2003)

Demonstrated mortality reduction in ACE-intolerant HFrEF patients with candesartan.

• Val-HeFT (2001)

Showed decreased HF hospitalizations and a trend toward reduced mortality with valsartan.

• CHARM-Overall (2003)

Large combined analysis confirming survival benefit.

---

2. SGLT2 Inhibitors — ~14% Mortality Reduction

Initially diabetes drugs, SGLT2 inhibitors became major HF therapies regardless of diabetic status.

They improve cardiac energetics, reduce preload/afterload, and promote natriuresis.

Landmark Trials

• DAPA-HF (2019) – Dapagliflozin

Reduced CV death and HF hospitalizations in HFrEF with or without diabetes.

• EMPEROR-Reduced (2020) – Empagliflozin

Confirmed class-effect benefits with reduced HF hospitalizations and slower renal decline.

---

3. ARNI (Sacubitril/Valsartan) — ~20% Mortality Reduction

Angiotensin receptor–neprilysin inhibition is superior to traditional RAAS inhibition alone.

Corrected benefit clause: Superior to ARB.

Landmark Trial

• PARADIGM-HF (2014)

One of the most practice-changing HF trials ever performed.

Showed 20% reduction in CV death, 16% reduction in all-cause mortality, and fewer HF admissions compared with enalapril.

---

4. ACE Inhibitors — ~27% Mortality Reduction

ACEIs were the first class to conclusively prove mortality reduction in chronic HF.

Landmark Trials

• CONSENSUS (1987)

Enalapril significantly reduced mortality in severe HF (NYHA IV).

• SOLVD-Treatment (1991)

Confirmed mortality and hospitalization reduction in mild-moderate HF.

• SAVE (1992)

Captopril improved survival post-MI in LV dysfunction.

---

5. Mineralocorticoid Receptor Antagonists (Spironolactone/Eplerenone) — ~30% Mortality Reduction

MRAs block aldosterone-mediated fibrosis, remodeling, and sodium retention.

Landmark Trials

• RALES (1999) – Spironolactone

Massive 30% reduction in all-cause mortality in severe HF.

• EPHESUS (2003) – Eplerenone

Reduced mortality in LV dysfunction post-MI.

• EMPHASIS-HF (2011) – Eplerenone

Showed dramatic benefit even in mild HF (NYHA II).

---

6. ICD (Implantable Cardioverter-Defibrillator) — ~31% Mortality Reduction

ICDs prevent sudden cardiac death due to ventricular arrhythmias in HFrEF.

Landmark Trials

• MADIT-II (2002)

ICDs reduce mortality in ischemic cardiomyopathy with EF ≤30%.

• SCD-HeFT (2005)

ICDs lowered all-cause mortality in both ischemic & non-ischemic HF with EF ≤35%.

---

7. β-Blockers — ~35% Mortality Reduction

β-blockers remain one of the strongest therapies, counteracting sympathetic overdrive and remodeling.

Landmark Trials

• MERIT-HF (1999) – Metoprolol CR/XL

Reduced all-cause mortality by 34% in HFrEF.

• CIBIS-II (1999) – Bisoprolol

Showed 32% reduction in all-cause mortality.

• COPERNICUS (2001) – Carvedilol

Benefits even in severe HF (NYHA IV).

---

8. CRT (Cardiac Resynchronization Therapy) — ~36% Mortality Reduction

CRT improves electrical synchrony, LV function, and quality of life.

Landmark Trials

• COMPANION (2004)

CRT-P and CRT-D reduced all-cause mortality and HF hospitalization.

• CARE-HF (2005)

CRT reduced mortality by 36%—independent of ICD therapy.

---

9. Hydralazine + Isosorbide Dinitrate (H-ISDN) in Black Patients — ~43% Mortality Reduction

This combination offers preload and afterload reduction with marked survival benefit, especially in Black patients.

Landmark Trial

• A-HEFT (2004)

One of the most striking findings in HF therapy:

43% reduction in mortality and 33% reduction in hospitalizations in Black patients with NYHA III–IV HFrEF.

Conclusion

The treatment of HFrEF has evolved profoundly through robust evidence from landmark trials. Modern therapy aims to rapidly initiate all four pillars—ARNI/ACEI/ARB, β-blockers, SGLT2 inhibitors, and MRAs—while considering device therapy (ICD/CRT) and H-ISDN when appropriate.

Together, these therapies can more than halve mortality and dramatically improve quality of life for patients living with heart failure.